Big Pharma · Oncology · United States

AstraZeneca — Oncology in United States

OncologyRare DiseaseImmunologyCardiometabolic
Commission a AstraZeneca report

AXLRx AstraZeneca intelligence — Oncology in United States: 1 report covering Oncology in United States.

All areas NeurologyImmunologyMetabolicOncologyRare Disease
Market: All United States
Market access — United States

Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.

AXLRx reports featuring AstraZeneca — Oncology in United States
NSCLC
CI
CI Oncology CI TeamLaunch Lead

US NSCLC Competitive Intelligence

Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.

US In-Market Read report →